Molecular imaging of proliferation in malignant lymphoma

Cancer Research

Volumn 66, Issue 22, 2006, Pages 11055-11061

  Buck, Andreas K ^a   Bommer, Martin ^a   Stilgenbauer, Stephan ^a   Juweid, Malik ^b   Glatting, Gerhard ^a   Schirrmeister, Holger ^a   Mattfeldt, Torsten ^a   Tepsic, Djurdja ^a   Bunjes, Donald ^a   Mottaghy, Felix M ^a   Krause, Bernd J ^a   Neumaier, Bernd ^a   Döhner, Hartmut ^a   Möller, Peter ^a   Reske, Sven N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY 3'[18 FLUORINE]FLUOROTHYMIDINE; FLUORODEOXYGLUCOSE; KI 67 ANTIGEN; THYMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CALCULATION; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; LYMPHOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARDIZATION; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33845337655     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1955     Document Type: Article

References (31)

1. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81.
2. 18F]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
3. 18F]fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
4. Rodriguez M, Rehn S, Ahlstrom H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
5. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522-7.
6. 18F]Fluorodeoxyglucose uptake in PET distinguishes between indolent and aggressive non-Hodgkin's lymphomas. J Clin Oncol 2005;23:4643-51.
7. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
8. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-30.
9. 18F]fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-63.
10. Kubota R, Kubota K, Yamada S, et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues, and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994;35:104-12.
11. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77.
12. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 1988;29:1633-7.
13. 11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002;62:5698-702.
14. 18F]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
15. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
16. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
17. 18F]FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7.
18. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
19. Jaffe ES, Harris NL, Stein H, et al. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
20. 18F]FLT). J Radioanal Nucl Chem 2000;24:843-6.
21. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005;32:525-33.
22. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994;21:930-6.
23. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999;34:545-51.
24. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001;115:793-800.
25. 18F]FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12:825-30.
26. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23.
27. Lu L, Samuelsson L, Bergstrom M, et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688-98.
28. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.
29. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
30. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.
31. 18F]FLT for monitoring response to antiproliferative therapy in a mouse lymphoma xenotransplant model. J Nucl Med 2004;45:434.